Zobrazeno 1 - 10
of 76
pro vyhledávání: ''
Publikováno v:
International Journal of Gynecologic Cancer. 31:824-828
ObjectiveIn this study we investigated response rates of bevacizumab in addition to weekly paclitaxel and carboplatin in neoadjuvant setting in cervical cancer stage IB–IIB.MethodsIn this retrospective study we included patients with FIGO 2018 stag
Autor:
Hee Seung Kim, Hyunhoon Chung, Se Ik Kim, Eun Ji Lee, Maria Lee, Jae Weon Kim, Yong Sang Song, Noh Hyun Park
Publikováno v:
International Journal of Gynecologic Cancer. 30:1943-1950
ObjectiveEvidence on recurrence patterns after bevacizumab in epithelial ovarian cancer is still insufficient. The aim of this study was to evaluate recurrence patterns after treatment with bevacizumab as second-line treatment in patients with platin
Autor:
Alexander Burges, Christian Kurzeder, Frederik Marmé, Florian Heitz, Andrés Redondo, Kristina Lindemann, Domenica Lorusso, Patricia Pautier, Nadin Cron, Pauline Wimberger, Jonathan A. Ledermann, Philipp Harter, Xavier Paoletti, Edgar Petru, Jalid Sehouli, Alexander Reuss, Nikolaus Degregorio, Els Van Nieuwenhuysen
Publikováno v:
International Journal of Gynecologic Cancer. 30:1997-2001
BackgroundImprovement in clinical outcomes of patients with platinum-resistant disease is an unmet medical need and trials in this population are urgently needed. Checkpoint-inhibitors have already shown activity in multiple other tumor entities and
Autor:
Clare Green, Gianfilippo Bertelli, Marcia Hall, Chit Cheng Yeoh, Steve Chan, Timothy J. Perren, Louise Li, Agnes Ograbek, Rachel Jones, Jurjees Hasan
Publikováno v:
International Journal of Gynecologic Cancer. 30:213-220
ObjectiveTwo randomized phase III trials demonstrated the efficacy and safety of combining bevacizumab with front-line carboplatin/paclitaxel for advanced ovarian cancer. The OSCAR (NCT01863693) study assessed the impact of front-line bevacizumab-con
Autor:
Josephine S. Kim, Kristine R. Penner, Chi E Wang, Rebecca A. Brooks, Jean A. Hurteau, Margaret I. Liang, Jill Alldredge, Tilley Jenkins Vogel, Carolyn V. Kirschner, Joshua G. Cohen, Avisek Datta, Ilana Cass, Gustavo C. Rodriguez, E.N. Prendergast, E.D. Moore
Publikováno v:
Int J Gynecol Cancer
ObjectivesTo compare clinical outcomes for stage IIIC and IV ovarian cancer patients receiving neoadjuvant chemotherapy and interval cytoreductive surgery followed by up to three versus more cycles of post-operative chemotherapy.MethodsWe conducted a
Autor:
Ana de Juan Ferré, Isabel Bover Barcelo, Margarita Romeo Marin, M. Gil-Martin, Aránzazu Manzano, Y. García, Lydia Gaba Garcia, Cristina Arqueros Núñez, Maria-Pilar Barretina-Ginesta, Elena García-Martínez, Antonio Gonzalez Martin, Cesar Mendiola, Maria Jesús Rubio Pérez, Ana Santaballa Bertrán
Publikováno v:
International Journal of Gynecologic Cancer. 29:1050-1056
BackgroundBevacizumab is an approved treatment after primary debulking surgery for ovarian cancer. However, there is limited information on bevacizumab added to neoadjuvant chemotherapy before interval debulking surgery.ObjectiveTo evaluate neoadjuva
Publikováno v:
International Journal of Gynecologic Cancer. 29:787-791
ObjectiveTo analyze the clinical characteristics, diagnosis, and treatment of ovarian juvenile granulosa cell tumor.MethodsThe clinical and pathological data of six patients with ovarian juvenile granulosa cell tumor was collected.ResultsThe mean age
Role of salvage therapy in chemo resistant or recurrent high-risk gestational trophoblastic neoplasm
Autor:
Vijay C R, Arpitha Anantharaju, K Shobha, U. D. Bafna, Rajshekar Kundargi, V R Pallavi, Praveen S. Rathod
Publikováno v:
International Journal of Gynecologic Cancer. 29:547-553
ObjectivesTo assess the importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia (HR GTN) after failure of first line multiagent chemotherapy.MethodsThis retrospective study involving women with HR GTN treated
Autor:
Sandro Pignata, Kathleen N. Moore
Publikováno v:
International Journal of Gynecologic Cancer. 29:430-433
BackgroundThere is mounting pre-clinical and clinical evidence that combinations of immunotherapy, specifically programed cell death-1 (PD-1) inhibition, with chemotherapy and anti-angiogenesis agents, such as bevacizumab, result in markedly improved
Autor:
Tadashi Kimura, Fuminori Kitada, Kotaro Shimura, Yuri Matsumoto, Naoko Komura, Eriko Yokoi, Aki Isobe, Seiji Mabuchi, Kenjiro Sawada, Tateki Tsutsui
Publikováno v:
International Journal of Gynecologic Cancer. 29:474-479
ObjectivesWe conducted a phase II study to investigate the efficacy and toxicities of irinotecan plus oral S-1 in patients with advanced or recurrent uterine cervical cancer.MethodsPatients with advanced or recurrent cervical cancer previously treate